Remibrutinib phase 2 trial reduce ESSDAI
Donald Thomas
Visit
ard.bmj.com
to learn more
February 15, 2024
7 hr
Log in Sign Up
Channels
DiscoveryCardiology
every day
COVID
every day
Dermatology
every day
Endocrinology
every dayendo22ata22
Gastroenterology
every day
Hematology
every day
Hepatology
every day
Nephrology
every daynkfscm22kidneywk22asn23
Oncology
every dayesmo22
Ophthalmology
every dayaao23arvo2024visions2024aao22arvo22aao21wio22
Primary Care
every day
Pulmonology
every day
Rheumatology
every dayacr23acr22hiv
Urology
every day
Speaker
Remibrutinib phase 2 trial reduce ESSDAI